A survey of 103 American dermatologists has provided some information on prescribing practices in the management of psoriasis.
The report from Spherix Global Insights finds that, compared to the same quarter last year, the share in the biologic market held by interleukin (IL)-17 inhibitors has doubled, fueled by the introduction of Eli Lilly's (NYSE: LLY) Taltz (ixekizumab) and the growing popularity of Novartis' (NOVN: VX) Cosentyx (secukinumab).
Despite rock bottom pricing, Valeant Pharmaceuticals (TSX: VRX) is not performing well with its IL-17 product Siliq (brodalumab).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze